Streetbeat News

TMBR

Timber Pharmaceuticals Inc

Employees

Industry

Medicinal and Botanical Manufacturing

timber pharmaceuticals llc, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. the company was founded in 2019 and is based in woodcliff lake, new jersey.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

U.S. stocks traded mixed with the Dow Jones falling over 100 points while NASDAQ and S&P 500 rose. Palo Alto Networks reported better-than-expected Q4 earnings and issued a strong billings outlook, causing its shares to rise by 17%. Timber Pharmaceuticals' shares spiked by 98% as it agreed to be acquired by LEO US Holding. Moderna's shares also rose by 9% after announcing positive preliminary clinical trial data for its updated COVID-19 vaccine. Meanwhile, shares of Super League Gaming, Napco Security Technologies, and PARTS iD fell significantly.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 4:45 pm

Timber Pharmaceuticals has announced a definitive agreement to be acquired by LEO Pharma for up to $36 million, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:19 pm

US stocks traded mostly higher with the Nasdaq Composite gaining over 100 points. Palo Alto Networks (PANW) reported better-than-expected Q4 earnings and issued a strong billings outlook. China SXT Pharmaceuticals (SXTC), Timber Pharmaceuticals (TMBR), and Waldencast (WALD) saw significant stock increases. Super League Gaming (SLGG), Napco Security Technologies (NSSC), and PARTS iD (ID) experienced notable stock decreases.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 2:14 pm

Timber Pharmaceuticals, Inc. (NYSE:TMBR) has agreed to be acquired by LEO US Holding, Inc., a subsidiary of LEO Pharma A/S, for a total transaction value of $36 million. The deal includes an initial upfront consideration of $14 million and up to an additional $22 million in contingent value rights (CVRs) payable upon achievement of certain milestones. The transaction is expected to close in 4Q23, after which Timber will become a privately held company.

Portfolio Pulse from Akanksha Bakshi

August 21, 2023 | 1:42 pm

During Monday's pre-market session, several healthcare stocks experienced significant movement. Timber Pharmaceuticals (TMBR), China SXT Pharmaceuticals (SXTC), China Pharma Holding (CPHI), Strata Skin Sciences (SSKN), Anebulo Pharmaceuticals (ANEB), and NanoVibronix (NAOV) saw their shares rise, while Assure Hldgs (IONM), Connect Biopharma Hldgs (CNTB), SHL Telemedicine (SHLT), Alpha Tau Medical (DRTS), OKYO Pharma (OKYO), and Predictive Oncology (POAI) experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 1:06 pm

Timber Pharmaceuticals has agreed to be acquired by LEO Pharma for up to $36M, including an initial upfront consideration of $14M and up to an additional $22M in contingent value rights.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:03 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. Adial Pharmaceuticals, Aytu BioPharma, Timber Pharmaceuticals, Mainz Biomed, Processa Pharma, and AIM ImmunoTech saw gains, while Assure Hldgs, T2 Biosystems, Biote, OpGen, Biophytis, and NeuroBo Pharmaceuticals experienced losses. Q2 earnings reports were recently released for several of these companies.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 9:32 pm

In Friday's pre-market session, several healthcare stocks saw significant movement. Alpha Tau Medical, NeuBase Therapeutics, Avalo Therapeutics, Timber Pharmaceuticals, AcelRx Pharmaceuticals, and TRACON Pharma all saw increases in their share prices. Conversely, Athersys, CervoMed, Bone Biologics, Scilex Holding, Predictive Oncology, and NRX Pharmaceuticals all experienced decreases.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 1:06 pm

Timber Pharmaceuticals announced interim pharmacokinetic analyses from the Phase 3 ASCEND study, indicating minimal systemic absorption of isotretinoin in patients with congenital ichthyosis treated with TMB-001. The full results will be presented at the Society for Pediatric Dermatology's Annual Meeting.

Portfolio Pulse from Happy Mohamed

June 20, 2023 | 12:20 pm

Bluejay Diagnostics shares are trading lower by 12% in pre-market trading. The article also lists 20 stocks moving premarket, with Visionary Education Technology Holdings Group, Chijet Motor Company, and Secoo Holding Limited among the top gainers, while HTG Molecular Diagnostics, Pasithea Therapeutics Corp, and Sono Group N.V. are among the top losers.

Portfolio Pulse from Lisa Levin

June 06, 2023 | 12:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.